IVERIC bio (NASDAQ:ISEE) Releases Earnings Results

IVERIC bio (NASDAQ:ISEE) released its quarterly earnings results on Thursday. The company reported ($0.35) EPS for the quarter, Morningstar.com reports.

Shares of IVERIC bio stock traded down $0.01 during midday trading on Friday, hitting $1.16. The company had a trading volume of 221,062 shares, compared to its average volume of 78,342. The company’s 50 day moving average price is $1.25. The company has a market cap of $49.36 million, a PE ratio of -0.69 and a beta of 1.17. IVERIC bio has a 1-year low of $1.02 and a 1-year high of $2.60.

In related news, insider Glenn Sblendorio acquired 25,000 shares of the stock in a transaction dated Friday, May 10th. The shares were acquired at an average price of $1.48 per share, for a total transaction of $37,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 4.30% of the company’s stock.

A hedge fund recently bought a new stake in IVERIC bio stock. Gabelli Funds LLC acquired a new position in IVERIC bio Inc (NASDAQ:ISEE) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 20,000 shares of the company’s stock, valued at approximately $26,000. Institutional investors and hedge funds own 40.57% of the company’s stock.

A number of equities analysts have recently commented on ISEE shares. Zacks Investment Research lowered shares of IVERIC bio from a “hold” rating to a “sell” rating in a research report on Tuesday, June 4th. ValuEngine raised shares of IVERIC bio from a “hold” rating to a “buy” rating in a research report on Thursday.

About IVERIC bio

IVERIC bio, Inc, a biopharmaceutical company, develops novel therapies to treat ophthalmic diseases with a focus on age-related and orphan retinal diseases. The company is developing Zimura, an inhibitor of complement factor C5, which is in Phase IIb clinical trials for the treatment of geographic atrophy (GA), a late-stage form of dry age-related macular degeneration (AMD) characterized by retinal cell death and degeneration of tissue in the central portion of the retina known as the macula; and autosomal recessive Stargardt disease (STGD1), which is an orphan inherited retinal disease (IRD).

Further Reading: What Is An Exchange-Traded Fund (ETF)?

Earnings History for IVERIC bio (NASDAQ:ISEE)

Receive News & Ratings for IVERIC bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IVERIC bio and related companies with MarketBeat.com's FREE daily email newsletter.